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(QALYs) gained. Model probabilities were obtained from a systematic review involv-
ing international published trials. Comparators used in the assessment were lorazepam 
(6 mg/day); alprazolam (1.5 mg/day); venlafaxine (75 mg/day) and pregabalin (150–
600 mg/day). Resource use and costs were obtained by a panel of Mexican experts 
through the Delphi technique and ofﬁ cial institutional databases. Costs include out-
patient and inpatient services, drug, procedures, etc. The model was validated accord-
ing to international guidelines. One-way and probabilistic sensitivity analyses were 
performed and acceptability curves were constructed. RESULTS: Pregabalin had the 
highest percentage of patients with over 50% reduction on the HAM-A scale (64.7%);
followed by venlafaxine (54.1%), lorazepam (40.8%) and alprazolam (38.2%). 
Regarding QALYs the highest results corresponded to pregabalin (0.1838QALYs);
followed by venlafaxine (0.1787QALYs), alprazolam (0.1776QALYs) and lorazepam 
(0.1753QALYs). The 12-week expected mean costs per patient were US$1525.0 o
531.3; US$1532.6 o 548.3; US$1582.2 o 573.0 and US$1,635 o 604.6; respectively
following the last order above. The ICER for pregabalin vs. venlafaxine (baseline) was
US$465.7 for HAM-A and US$26,075.7 for QALYs. Pregabalin dominated lorazepam 
and alprazolam (p  0.05). First-order Monte Carlo sensitivity analyses showed results 
robustness and that pregabalin was the most cost-effective therapy using international 
thresholds. CONCLUSIONS: Pregabalin showed to be a cost-effective and cost-saving
therapy in the management of Mexican patients with GAD.
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OBJECTIVES: The present cost-effectiveness analyses compare escitalopram versus 
duloxetine and generic venlafaxine in second-line MDD treatment, to inform decision-
making on efﬁ cient second-line therapy choice. METHODS: A decision model was 
based on second-line MDD treatment patterns (6-month timeframe). Effectiveness 
outcomes were sustained remission (the Montgomery-Asberg Depression Rating Scale 
(MADRS) a12 at 2 months, sustained till the end of, month 6) and quality-adjusted
life years (QALY). Total cost included health care and absenteeism costs. Clinical
inputs were derived from pooled analyses of randomized clinical trials on the second-
line patients subgroup. Health care resource utilization was assessed from a Swedish
observational cohort (HEADIS) and UK General Practice Research Database (GPRD). 
Utility estimates were based on HEADIS and US panel survey. Unit costs were from
standard sources. Due to unavailability of generic venlafaxine unit cost, it was 
assumed equal to that of escitalopram in Scenario 1, and 5% of the brand venlafaxine
cost in Scenario 2. RESULTS: Over 6 months, a sustained remission rate was 56% 
for escitalopram and 38% for SNRIs (18% difference, 95% Credibility Interval (CrI) 
0.8% to 32.9%)). The incremental QALY for escitalopram versus both comparators
was 0.024 (95% CrI 0.006 to 0.042). Per patient savings with escitalopram versus 
venlafaxine were 670 USD (95% CrI 6689 to 4481) in Scenario 1 and US$565 USD
(95% CrI 6588 to 4583) in Scenario 2. Versus duloxetine, savings were USD615, 
95% CrI (6670 to 4554). With willingness to pay 42,500 USD (equivalent to 350,000
SEK) per QALY, escitalopram was cost effective versus venlafaxine with probabilities 
86% and 61.7% in Scenarios 1 and 2, respectively, and with 85.4% probability versus 
duloxetine. CONCLUSIONS: Escitalopram is cost-effective versus venlafaxine and 
duloxetine in second-line treatment of MDD in Sweden. The higher sustained remis-
sion rate and QALYs are associated with cost savings and support use of escitalopram 
following failure of ﬁ rst-line treatment.
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OBJECTIVES: Many patients on antidepressants are not responsive to ﬁ rst-line
therapy (‘treatment-resistant’ depression [TRD]) and can undergo switches and opti-
mizations to discover a beneﬁ cial therapeutic regimen. While patients with more
complex forms of TRD have higher costs than non-TRD patients, little is known about
the cost effects for patients along a gradient of TRD classiﬁ cations (from moderate to
complex). METHODS: Patients aged 18–64 years in employer-sponsored plans with 
at least three years of continuous medical and prescription coverage and at least one 
antidepressant prescription were found in the 2000–2006 MarketScan Database (n 
78,476). An MGH TRD scale value (range from 0 to 16.5) was calculated for each
patient and a value exceeding 3.5 indicated TRD. Twelve-month direct medical and 
prescription drug expenditures for patients with TRD (n  22,593) were compared to
expenditures among an equal number of propensity-score matched patients with non-
TRD depression. Propensity scores were estimated via demographic characteristics and 
case-mix. Generalized linear models (gamma family and log link) controlled for 
demographic and case-mix factors. RESULTS: Average 12-month direct medical care
and prescription drug expenditures were almost 40% higher for TRD ($9470) com-
pared to matched non-TRD patients ($6813) (p  0.01). A one-unit increase in TRD 
score was associated with a $772 increase in annual costs (p  0.01). Compared with
a matched group of non-TRD patients, annual costs for patients were higher in each
MGH score catergory: 3.5–4, 23.6%; 4.5–5, 32.9%; 5.5–6, 44.6%; 6.5, 61.1% (all 
p  0.01). CONCLUSIONS: TRD is a costly disorder and merits consideration as
interventions are developed to manage the burden of disease and improve productivity. 
Even patients with less complex forms of TRD have costs far in excess of those without
TRD. Dichotomous deﬁ nitions of TRD may not be adequate; a gradient from moder-
ate to complex TRD may be more useful for providers and insurers.
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OBJECTIVES: Schizophrenia, inﬂ uencing approximately 1% of the population, is a
chronic psychiatric disease with a substantial health and economical burden for 
patients, care givers, and society. Despite this, however, its economic burden is often
overlooked and/or not widely known in many countries. This study aims at estimation 
of cost of schizophrenia treatment in an inpatient facility in Turkey. METHODS: The 
study has been conducted in Manisa Mental Diseases Training and Research Hospital, 
one of the largest of its type in Turkey. Electronic hospital records of 4177 schizo-
phrenia patients between June 2006 and June 2007 were retrospectively analyzed to 
calculate the total schizophrenia treatment cost per hospitalization where only direct 
costs were included. Cost items included in the analyses were antipsychotic and con-
comitant medication costs, adverse event treatment costs, bed costs, and laboratory/
radiological examination costs. Average length of stay per hospitalization was calcu-
lated. Results were presented as average daily and total costs of treatment per hospi-
talization. Composition of the total cost was also presented. RESULTS: Mean length 
of stay per hospitalization was 30.80 o 17.18 days. Mean daily total cost was TL
52.68 o 41.30. Mean total treatment cost per hospitalization was TL 1431.86 o
798.74. Costs for antipsychotic drugs, concomitant medications, adverse event 
treatment, bed, and laboratory/radiological examinations were 31%, 2%, 1%, 40%, 
and 26% respectively. CONCLUSIONS: The share of drug costs may be relatively 
higher than they are in other countries due to relatively lower costs for non-drug
cost items in Turkey. This may also stem from the case-mix in this hospital that may 
care more for severe cases needing tertiary care. This study may stimulate further
studies which would help to generate a fuller picture of economic burden of schizo-
phrenia in Turkey.
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OBJECTIVES: Compare direct (medical and drug) costs between privately insured 
U.S. employees with major depressive disorder (MDD) who had treatment-resistant 
depression (TRD) and matched antidepressant-treated MDD controls without TRD. 
METHODS: Employees with 1 inpatient or 2 outpatient/other MDD diagnoses 
(ICD-9-CM: 296.2, 296.3) during 2004–2006, ages 18–64 years, were selected from 
a claims database. Employees who initiated a third antidepressant following 2 anti-
depressant treatments of adequate dose and duration were classiﬁ ed as TRD-likely (n
 2,534). The index date was the date of ﬁ rst antidepressant. Control group was an 
age and gender matched cohort of randomly chosen antidepressant-treated employees 
with MDD without TRD. All were required to have continuous health coverage during 
the 6-month pre-index (baseline) and 12-month post-index (study) period. McNemar 
tests were used to compare baseline comorbidities. Wilcoxon signed-rank tests were 
used to compare annual per patient direct costs from third party payer perspective 
during the study period. Mental health (MH) related costs were identiﬁ ed by claims 
with MH disorder diagnosis (ICD-9-CM: 290–319) or MH-related drug costs.
RESULTS: TRD-likely employees with MDD were on average 49.2 years old and
60.7% were women. Compared with controls, TRD-likely employees had signiﬁ cantly
higher rates of MH disorders, chronic pain, ﬁ bromyalgia, but few differences in
comorbidities included in the Charlson Comorbidity Index. Average direct annual
costs were signiﬁ cantly higher for TRD-likely employees ($10,136) compared 
with controls ($7,793), $2,393 difference, p  0.0001. Average MH-related costs
were higher among TRD-likely employees ($2,714) compared with controls ($1,256),
p  .0001; the MH-related cost difference of $1,958 accounted for 62.2% of the 
direct cost difference. MH-related cost differences were attributable to differences
in drug 52.9% outpatient (929.3), inpatient (12.92%), costs. CONCLUSIONS:
TRD-likely employees with MDD had higher all-cause and MH-related direct costs
compared with matched MDD controls. Excess costs of TRD-likely patients are 
underestimated when looking only at MH-related costs.
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OBJECTIVES: Compare comorbidity proﬁ les and direct costs in older patients with
depression treated or untreated with antidepressants and matched controls without 
depression. METHODS: Administrative claims from a multi-specialty medical group
A178 Abstracts
practice in central Massachusetts were used to identify 1777 patients age q65 years 
as of January 1, 2006 with continuous medical and pharmacy coverage in 2005 
(baseline) and 2006 (study period) and q1 depression diagnosis in 2005. Patients with 
q1 antidepressant claim in 2006 were classiﬁ ed as “treated” and those without an 
antidepressant as “untreated.” Depressed patients were randomly matched to controls 
without depression on age and gender. Baseline comorbidity proﬁ les were compared 
using Chi-square tests. Wilcoxon rank-sum tests and generalized linear models were
used to compare study period direct (medical and pharmacy) costs deﬁ ned as third 
party payments to providers. Depression-related costs were identiﬁ ed using claims
with depression diagnosis and antidepressant prescriptions. RESULTS: A total of 1334 
(75.1%) of depressed patients were treated with antidepressants during the study
period and 443 patients (24.9%) were not treated. Depressed patients were on average 
77 years old and 74.8% were women. Depressed patients had higher rates of mental 
health and physical comorbidities than controls. Treated depressed patients had higher 
rates of mental health comorbidities than the untreated but few differences in rates of 
physical comorbidities. During the study period average annual direct costs were
$14,362 among treated depressed patients, $8,928 among the untreated, and $6,961 
among controls (P  0.01 for all comparisons). Risk-adjusted direct costs were
signiﬁ cantly different between the treated and untreated depressed. Average depres-
sion-related costs were $1,582 among the treated and $133 among the untreated (P
 0.01). CONCLUSIONS: Older depressed patients (both treated and untreated) had
more comorbidities and higher costs compared to controls. Costs and rates of mental
health comorbidities were higher among the treated depressed compared with the
untreated.
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OBJECTIVES: To estimate hospitalization costs as well as resources used by schizo-
phrenic patients during a relapse in a public psychiatric hospital. METHODS: A 
documental retrospective analysis of schizophrenia patients with a relapse as the 
principal diagnosis was carried out in a public psychiatric hospital in Mexico. The
range of patients’ age was from 18 to 64 years. Data was collected by a General Physi-
cian through a Case Report Form designed speciﬁ cally for this study. Resources used 
during relapse hospitalization were accrued and ﬁ nal costs were calculated using
unitary costs of the Mexican Social Security Institute (IMSS) for laboratory studies,
physician’s visit, emergency admittance and bed day. Drug costs were obtained from 
public bids of the same institution. Results are presented using descriptive statistics. 
Costs are in US dollars using and exchange rate of 13.5 MXN pesos for 1 US dollar. 
RESULTS: Sample size was of 73 patients with an average follow up of 3.3 years. 
Hospital average length of stay was 20.65 days (4–108), average time between relapses
was 14.66 months (6.47–25.73). The average cost per day was $346 (95% IC,
$331–$360), 96% of this cost represents the average bed day cost reported by the
IMSS. The average cost per relapse was $7,086 ($1,498–$36,288). Alcoholism and 
hypertension were the main comorbidities reported in 10.8% of admitted patients. 
Lack of compliance was the reason for relapse in 95% of the cases. CONCLUSIONS:
Bed day cost is the main component of total costs, therefore it would make sense to 
use those antipsychotic drugs that help reduce the hospital length of stay. The lack of 
compliance is responsible for the vast majority of relapses (95%). A health care 
program focus in increasing drug compliance could decrease institutional general costs
by reducing hospitalizations due to relapses.
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OBJECTIVES: Efﬁ cacy in bipolar disorder (BPD) has been demonstrated for various
atypical antipsychotics (APs). Treatment choice is based on factors including patient
history and clinician preference. Because cost of patient care is often a factor, this
study explored the association between AP treatment choice and subsequent medical 
care costs. METHODS: Patients with BPD and AP treatment were identiﬁ ed in the
2004–2005 PharMetrics Patient-Centric Database. Patients were stratiﬁ ed by the 
most-recently prescribed AP and retained with q12 months continuous enrollment 
before and after their earliest AP claim. Total medical care costs were tallied from all
paid claims for 12 months post AP initiation. Multivariable analyses controlled for 
differences between cohorts. RESULTS: AP patient cohorts were ziprasidone (n  825), 
olanzapine (n  2526), risperidone (n  2309), quetiapine (n  2860) and aripiprazole
(n  1187). Mean age was 39–42 years. Ziprasidone patients were more likely to be 
female. Approximately 25% of the sample had comorbid anxiety and 10% had 
alcohol abuse. The majority had concomitant medication use. After controlling for 
covariates, the ziprasidone group’s 12-month post-initiation total costs ($14,445) were
similar to risperidone ($13,358, p  .06) and olanzapine ($13,780, p  0.24), and,
lower than quetiapine ($15,740, p  0.03) and aripiprazole ($16,360, p  0.01). Older 
age, female gender, pre-index psychiatric admission, comorbidities, and concomitant 
medication were signiﬁ cantly associated with increased costs. Nevertheless, unadjusted
results were similar to multivariable ﬁ ndings. CONCLUSIONS: Twelve months fol-
lowing treatment initiation for BPD, total medical care costs for patients on ziprasi-
done were comparable to those for patients on olanzapine or risperidone, and, 
signiﬁ cantly lower than costs for patients on quetiapine or aripiprazole. If cost is a
factor in AP treatment choice, the ﬁ ndings suggest ziprasidone compares favorably.
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OBJECTIVES: Efﬁ cacy in treating schizophrenia has been demonstrated for a variety 
of atypical antipsychotics (APs). Clinicians will select an appropriate AP based on a
variety of clinical considerations but cost of patient care is increasingly becoming a 
consideration. This study explored the association between AP treatment choice and 
subsequent medical care costs. METHODS: Patients with schizophrenia and AP treat-
ment were identiﬁ ed in the 2004–2005 PharMetrics Patient-Centric Database. Patients
were stratiﬁ ed by the most-recently prescribed AP and retained with q12 months 
continuous enrollment before and after their earliest AP claim. Total and psychiatric-
related medical care costs were tallied from all paid claims for 12 months post AP 
initiation. Multivariable analyses controlled for differences between cohorts.
RESULTS: Patient cohorts were ziprasidone (n  207), olanzapine (n  755), risperi-
done (n  1004), quetiapine (n  404) and aripiprazole (n  367). Mean age was 40–44 
years. Mood disorders, anxiety, alcohol abuse and substance abuse were prevalent 
among the sample. Most patients had concomitant medication use. After controlling 
for covariates, the ziprasidone group’s 12-month post-initiation total costs ($12,920) 
were similar to risperidone ($11,522, p  0.14), olanzapine ($13,398, p  0.65), que-
tiapine ($14,076, p  0.32) and aripiprazole ($13,286, p  0.75). Psychiatric-related
costs accounted for roughly half of total costs and were comparable across cohorts.
Comorbidities and concomitant medication were signiﬁ cantly associated with 
increased costs. Nevertheless, unadjusted results were similar to multivariable ﬁ ndings. 
CONCLUSIONS: In the 12 months following AP initiation total medical care and 
psychiatric-related costs for schizophrenia patients on ziprasidone were comparable 
to those for patients on other APs. If cost is a factor in AP treatment choice, the ﬁ nd-
ings suggest ziprasidone compares favorably.
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OBJECTIVES: Dose escalation of antidepressant therapy is a common but potentially
costly strategy of managing treatment-refractory depression. This study assessed the
cost implications of dose escalation for major depressive disorder (MDD) patients
treated with escitalopram versus venlafaxine extended-release (XR). METHODS:
MDD patients (age q18) who started escitalopram or venlafaxine XR were identiﬁ ed
in the Ingenix Impact Database (2003–2006). The index date was the date when 
patients ﬁ rst received either drug at the label-recommended initial dose (escitalopram:
10 mg/day; venlafaxine XR: 75 mg/day) or high dose (escitalopram: 20 mg/day;
venlafaxine XR: 150 mg/day). Dose escalation was deﬁ ned as having a reﬁ ll with 
daily dose at least double the starting dose during the 6-month post-index period. A 
generalized linear model (GLM) assessed the effects of dose escalation and starting 
dose (recommended vs. high) on total health care costs during the post-index period, 
adjusting for index drug, demographics, comorbidities, and health care utilization at 
baseline. A similar GLM compared total costs between treatment groups, incorporat-
ing the effects of dose escalation and starting dose. RESULTS: 17,638 patients started
on escitalopram (18.6% on high-dose) and 9,252 on venlafaxine XR (46.0% on 
high-dose). Baseline mental comorbidities were similar between treatment groups. 
Venlafaxine XR patients had a 28.5% and 102.0% higher risk of dose escalation
compared to escitalopram patients in the recommended-dose and high-dose sub-
groups, respectively (both P  0.0001). Dose escalation and high starting dose were
associated with $1498 and $688 higher total costs, respectively (both P  0.0001). 
With lower starting dose and dose escalation risk, escitalopram patients incurred $198 
lower regression-adjusted total costs (P  0.0007) than venlafaxine XR patients. 
CONCLUSIONS: Dose escalation and high initial dose are associated with signiﬁ -
cantly higher total costs for adult MDD patients. Compared to venlafaxine XR 
patients, escitalopram patients are less likely to dose escalate or start on high-dose
treatment, and incur lower total costs.
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OBJECTIVES: Lisdexamfetamine dimesylate (LDX), a therapeutically inactive mole-
cule, which after ingestion, is converted to l-lysine, and therapeutically active d-
amphetamine, is the ﬁ rst recently approved long-acting (LA) prodrug stimulant
indicated for the treatment of attention-deﬁ cit hyperactivity disorder (ADHD) in 
children and adults. This study examined adult patients in a US commercial health 
